Concurrently, the indication for neoadjuvant chemotherapy has broadened, including patients with triple-negative BC and HER2-positive BC; in patients with pathological complete response, the omission of SLNB after neoadjuvant chemotherapy is now evaluated (EUBREAST-01 ClinicalTrials.gov Identifier: NCT04101851) [1, 17]. The gene discussed is ERBB2; the disease is breast cancer.